



1Pw

PATENT  
ATTORNEY DOCKET NO. 50026/055001

Certificate of Mailing: Date of Deposit: August 20, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Collette R. D'Amico

Printed name of person mailing correspondence

Collette R. D'Amico

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sueishi et al.

Confirmation No.: 2218

Serial No.: 10/549,474

Art Unit: 1615

371(c) Date: August 4, 2006

Examiner: Not Yet Assigned

Customer No.: 21559

Title: METHODS OF TREATING INFLAMMATORY DISEASES  
ASSOCIATED WITH BONE DESTRUCTION

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the reference listed on the enclosed Form PTO-1449, a copy of which is enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office Action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.


Respectfully submitted,

Date: 20 August 2007

  
\_\_\_\_\_  
James D. DeCamp, Ph.D.  
Reg. No. 43,580

*JAN N. TITRELL, Ph.D.  
Reg. No. 52,290*

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50026/055001
		Serial No.	10/549,474
		Applicant	Sueishi et al.
		371(c) Date	August 4, 2006
		Group	1615
		IDS Filed	August 20, 2007

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Guillonneau et al., "Fibroblast Growth Factor (FGF) Soluble Receptor 1 Acts as a Natural Inhibitor of FGF2 Neurotrophic Activity During Retinal Degeneration," <i>Molecular Biology of the Cell</i> 9(10):2785-2802 (1998).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	